ibalizumab

prevents entry of human immunodeficiency virus (HIV) into the host cell. TNX-355 binds to the CD4 receptor on the cell's surface, an entry gate for infection, preventing viral entry and thereby blocking infection.

Also Known As:

Networked: 21 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ho, David D: 3 articles (11/2013 - 12/2010)
2.	Seaman, Michael S: 3 articles (11/2013 - 12/2010)
3.	Kufel, Wesley D: 2 articles (12/2020 - 01/2019)
4.	Jacobson, Jeffrey M: 2 articles (01/2018 - 09/2010)
5.	Franco, David: 2 articles (11/2013 - 01/2013)
6.	Kao, Chia-Ying: 2 articles (01/2013 - 12/2010)
7.	Canetti, Diana: 1 article (03/2022)
8.	Castagna, Antonella: 1 article (03/2022)
9.	Feasi, Marcello: 1 article (03/2022)
10.	Galli, Laura: 1 article (03/2022)

Related Diseases

1.	Infections 02/01/2020 - "Although additional studies and long-term post-marketing data are needed to fully determine its efficacy and safety, ibalizumab represents a valuable and much needed treatment option for patients with multidrug-resistant HIV-1 infection." 01/01/2019 - "Clinical studies have demonstrated reasonably substantial antiretroviral activity with ibalizumab among a complex patient population with advanced HIV-1 infection who are receiving an optimized background regimen, where limited therapeutic options exist. " 01/01/2021 - "Ibalizumab may represent a cost-effective and affordable option to improve health outcomes for individuals with MDR HIV-1 infection." 01/01/2021 - "The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States." 01/01/2021 - "To review the efficacy and safety of ibalizumab (IBA) in the treatment of HIV-1 infection. "
2.	Nausea 01/01/2019 - "Ibalizumab is administered intravenously at a dose of 800 mg every 2 weeks following a single intravenous loading dose of 2000 mg. The most common adverse reactions reported with the use of ibalizumab are diarrhea, dizziness, nausea and rash." 01/01/2019 - "Ibalizumab was well tolerated in clinical trials, and the most common adverse effects included diarrhea, nausea, dizziness, fatigue, pyrexia, and rash. "
3.	Exanthema (Rash) 01/01/2019 - "Ibalizumab is administered intravenously at a dose of 800 mg every 2 weeks following a single intravenous loading dose of 2000 mg. The most common adverse reactions reported with the use of ibalizumab are diarrhea, dizziness, nausea and rash." 01/01/2019 - "Ibalizumab was well tolerated in clinical trials, and the most common adverse effects included diarrhea, nausea, dizziness, fatigue, pyrexia, and rash. "
4.	Dizziness (Lightheadedness) 01/01/2019 - "Ibalizumab is administered intravenously at a dose of 800 mg every 2 weeks following a single intravenous loading dose of 2000 mg. The most common adverse reactions reported with the use of ibalizumab are diarrhea, dizziness, nausea and rash." 01/01/2019 - "Ibalizumab was well tolerated in clinical trials, and the most common adverse effects included diarrhea, nausea, dizziness, fatigue, pyrexia, and rash. "
5.	Diarrhea 01/01/2019 - "Ibalizumab is administered intravenously at a dose of 800 mg every 2 weeks following a single intravenous loading dose of 2000 mg. The most common adverse reactions reported with the use of ibalizumab are diarrhea, dizziness, nausea and rash." 01/01/2019 - "Ibalizumab was well tolerated in clinical trials, and the most common adverse effects included diarrhea, nausea, dizziness, fatigue, pyrexia, and rash. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Antiviral Agents (Antivirals)
3.	ibalizumab
4.	Immunoglobulin G (IgG)
5.	Enfuvirtide (Fuzeon)
6.	burosumab
7.	tildrakizumab

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Bridge Therapy